FDA's Arthritis Advisory Committee
Executive Summary
Will meet Jan. 23 at FDA's Parklawn building, conference rooms G, H & I to discuss ICN/Viratek's Oxsoralen (8-methoxypsoralen) in combination with Therakos' UVAR Photopherisis System for the treatment of scleroderma. The combination therapy was reviewed by the committee on Dec. 6, 1990, when it was determined that the companies needed to perform further studies ("The Pink Sheet" Dec. 10, 1990, T&G-4). The meeting is set for 9 a.m. on Jan. 23. On Jan. 24, the committee will hold a closed session beginning at 8:30 a.m. to discuss INDs 30-150 and 22-545.